|
|
Post by BD on Apr 22, 2024 17:21:16 GMT -5
Thanks, cretin, the new avatar is a bit less hypnotic...
|
|
|
|
Post by ktim on Apr 23, 2024 8:51:38 GMT -5
In the green until exactly an hour before the market close. It’s almost as if somebody programs an algorithm to drive this stock down at prearranged times. So frustrating. That sounds like a pretty simple algorithm, assuming the computer has a clock. One would think it pretty easy to front run that. So you're saying given MNKD is up nicely now in the morning, all we need to do is short, and we'll make money today? Sometimes I wish I were smart enough to take advantage of these patterns that are apparently obvious. |
|
|
|
Post by cretin11 on Apr 23, 2024 10:10:29 GMT -5
In the green until exactly an hour before the market close. It’s almost as if somebody programs an algorithm to drive this stock down at prearranged times. So frustrating. That sounds like a pretty simple algorithm, assuming the computer has a clock. One would think it pretty easy to front run that. So you're saying given MNKD is up nicely now in the morning, all we need to do is short, and we'll make money today? Sometimes I wish I were smart enough to take advantage of these patterns that are apparently obvious. Would be risky to try to take advantage of that, given how often the opposite happens with MNKD making a nice run up on the last hour before close. I guess it’s human nature to not focus on those days but rather on the down days. |
|
|
|
Post by radgray68 on Apr 24, 2024 11:51:06 GMT -5
I’m waking up every day now looking for the notice of filing for one or both of the new drugs. Is it my imagination or were these pushed from Q1 to Q2?
I understand Clofazimine was delayed from Q4 because of the fire but is anybody a little concerned? The new chief medical guy must have dotted every I and crossed every T by now. Just my impatience peaking it’s ugly head out.
|
|
|
|
Post by radgray68 on Apr 25, 2024 15:19:26 GMT -5
Listened to the Oppenheimer conference again. We were waiting 30-45 days for feedback from the FDA before filing on 201 while 101 had just about finished chronic toxicity studies.
Mike was most excited about our 90 minute presentation on Saturday at 8:00am at ADA. Fingers crossed that we can cause an inflection in Afrezza after that.
Guess it’s hurry up and wait.
|
|
|
|
Post by runner on Apr 25, 2024 17:43:51 GMT -5
Rad, Where is Mike presenting this Saturday? I don’t see any information on the mnkd website
|
|
|
|
Post by Chris-C on Apr 26, 2024 11:52:19 GMT -5
That sounds like a pretty simple algorithm, assuming the computer has a clock. One would think it pretty easy to front run that. So you're saying given MNKD is up nicely now in the morning, all we need to do is short, and we'll make money today? Sometimes I wish I were smart enough to take advantage of these patterns that are apparently obvious. Would be risky to try to take advantage of that, given how often the opposite happens with MNKD making a nice run up on the last hour before close. I guess it’s human nature to not focus on those days but rather on the down days. I'd be more inclined to speculate that it has more to do with day traders who try to surf the waves and cash in before the market close to protect their gains. |
|
|
|
Post by radgray68 on Apr 26, 2024 12:29:04 GMT -5
Rad, Where is Mike presenting this Saturday? I don’t see any information on the mnkd website Sorry I should have specified. The ADA isn’t until June. We have a prime spot for presentations apparently. |
|
|
|
Post by agedhippie on Apr 26, 2024 13:03:27 GMT -5
I apologize in advance for the formatting. Carol Levy is interesting. She is part of the diabetes clinic I use and will be interest to see what she has to say. This is particularly interesting because she works with women who are pregnant and need to tightly control their levels.
-----
Symposium - The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Mulitple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (Includes Livestream)
Sat, Jun 22
W320 (Chapin Theater)
8:00am - 9:30am (Eastern)
Symposium
- Chair Roy W Beck
Presentation
Symposium
- Inhaled Insulin’s History and Study Rationale
8:00am-8:10am Jun 22 (Eastern)
Halis K Akturk
Presentation
Symposium
- Study Methods and Participant Baseline Characteristics
8:10am-8:20am Jun 22 (Eastern)
Yogish C Kudva
Presentation
Symposium
- Study Results I—Comparison of Inhaled Insulin vs. Rapid-Acting Analogue Insulin in Users of Automated Insulin Delivery or Multiple Daily Insulin Injections during Standardized In-Clinic Meal Challenges
8:20am-8:30am Jun 22 (Eastern)
Ruth S Weinstock
Presentation
Symposium
- Study Results II—Primary Efficacy, Safety, and Quality of Life Outcomes
8:30am-8:40am Jun 22 (Eastern)
Carol J Levy
Presentation
Symposium
- Study Results III—Effect of Inhaled Insulin-Degludec Compared with Automated Insulin Delivery and in Subgroups According to Participant Characteristics
8:40am-8:50am Jun 22 (Eastern)
Grazia Aleppo
Presentation
Symposium
- Critique of Study Design and Results
8:50am-9:00am Jun 22 (Eastern)
Irl B Hirsch
Presentation
Symposium
- Use of Inhaled Insulin in Clinical Practice
9:00am-9:10am Jun 22 (Eastern)
Thomas Blevins
Presentation
Symposium
- Question and Discussion Period
9:10am-9:30am Jun 22 (Eastern)
|
|
|
|
Post by sayhey24 on Apr 26, 2024 13:09:37 GMT -5
I apologize in advance for the formatting. Carol Levy is interesting. She is part of the diabetes clinic I use and will be interest to see what she has to say. This is particularly interesting because she works with women who are pregnant and need to tightly control their levels. ----- Symposium - The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Mulitple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (Includes Livestream) Sat, Jun 22 W320 (Chapin Theater) 8:00am - 9:30am (Eastern) Symposium - Chair Roy W Beck Presentation Symposium - Inhaled Insulin’s History and Study Rationale 8:00am-8:10am Jun 22 (Eastern) Halis K Akturk Presentation Symposium - Study Methods and Participant Baseline Characteristics 8:10am-8:20am Jun 22 (Eastern) Yogish C Kudva Presentation Symposium - Study Results I—Comparison of Inhaled Insulin vs. Rapid-Acting Analogue Insulin in Users of Automated Insulin Delivery or Multiple Daily Insulin Injections during Standardized In-Clinic Meal Challenges 8:20am-8:30am Jun 22 (Eastern) Ruth S Weinstock Presentation Symposium - Study Results II—Primary Efficacy, Safety, and Quality of Life Outcomes 8:30am-8:40am Jun 22 (Eastern) Carol J Levy Presentation Symposium - Study Results III—Effect of Inhaled Insulin-Degludec Compared with Automated Insulin Delivery and in Subgroups According to Participant Characteristics 8:40am-8:50am Jun 22 (Eastern) Grazia Aleppo Presentation Symposium - Critique of Study Design and Results 8:50am-9:00am Jun 22 (Eastern) Irl B Hirsch Presentation Symposium - Use of Inhaled Insulin in Clinical Practice 9:00am-9:10am Jun 22 (Eastern) Thomas Blevins Presentation Symposium - Question and Discussion Period 9:10am-9:30am Jun 22 (Eastern) How did she get involved with afrezza? Did you suggest it? |
|
|
|
Post by prcgorman2 on Apr 26, 2024 14:23:56 GMT -5
I see Irl B Hirsch serves up Thomas Blevins for the conclusion of the presentations. I don't know who Thomas Blevins is or Irl for that matter other than what I researched learning about him here but I think it is good to have a widely-respected subject matter expert set the table for you.
|
|
|
|
Post by agedhippie on Apr 26, 2024 15:47:09 GMT -5
I apologize in advance for the formatting. Carol Levy is interesting. She is part of the diabetes clinic I use and will be interest to see what she has to say. This is particularly interesting because she works with women who are pregnant and need to tightly control their levels. ... How did she get involved with afrezza? Did you suggest it? It's a trial, she will use whatever the protocol calls for. Beyond that I have no idea but I wouldn't tell a random endo in a team what to use - my own endo is a different matter  This is also a good example why you should use firms like Jaeb. They have a great deal of credibility in the diabetes arena so collaborators will work with them when they may well not be otherwise interested. |
|
|
|
Post by sayhey24 on Apr 27, 2024 8:00:24 GMT -5
How did she get involved with afrezza? Did you suggest it? It's a trial, she will use whatever the protocol calls for. Beyond that I have no idea but I wouldn't tell a random endo in a team what to use - my own endo is a different matter This is also a good example why you should use firms like Jaeb. They have a great deal of credibility in the diabetes arena so collaborators will work with them when they may well not be otherwise interested. Why not? I wouldn't think twice about talking about afrezza to anyone, especially a supposed "expert". Sometimes I learn something, sometimes they do. Then again I am a true believer. In this case she must see something in afrezza unless she just needed a payday which I hope is not the case. We will see on 6/22. As far as the speakers, I would hope Irl picked up the phone and made the invites. At the same time we need the best lobbyists we can get. |
|
|
|
Post by agedhippie on Apr 27, 2024 10:12:01 GMT -5
It's a trial, she will use whatever the protocol calls for. Beyond that I have no idea but I wouldn't tell a random endo in a team what to use - my own endo is a different matter This is also a good example why you should use firms like Jaeb. They have a great deal of credibility in the diabetes arena so collaborators will work with them when they may well not be otherwise interested. Why not? I wouldn't think twice about talking about afrezza to anyone, especially a supposed "expert". Sometimes I learn something, sometimes they do. Then again I am a true believer. In this case she must see something in afrezza unless she just needed a payday which I hope is not the case. ... Yeah. That's not how these places work. In summary - Yes, as a long time endo, and the head of Type 1 research at Mt Sinai she is an expert and not a supposed "expert". - Endos in that hospital system don't talk to sales reps, and definitely not random strangers wanting to tell them about "paradigm shifts"! - They have prescribed Afrezza in the past - Clinical trials like this are definitely not a money maker. As I have said in the past I donate to Mt Sinai so I get some sight of the research they are doing occasionally. Trials like this one are the sort of thing they do, but it needs to be credible which is where Jaeb comes in, it needs to be a multi-center trial (anything else is probably to small), and it needs to fit the research teams interest which I suspect in this case is if Afrezza is a viable option to an AID pump in pregnancy. The money they receive for this trial is unlikely to even cover their costs. |
|
